Literature DB >> 6333146

Cranial computed tomographic abnormalities in leptomeningeal metastasis.

Y Y Lee, J P Glass, A Geoffray, S Wallace.   

Abstract

Sixty-four (57.6%) of 111 cancer patients with cerebrospinal fluid cytology positive for malignant cells had cranial computed tomographic (CT) scans within 2 weeks before or after a lumbar puncture. Twenty-two (34.3%) of the 64 had abnormal CT findings indicative of leptomeningeal metastasis: (1) sulcal-cisternal enhancement, (2) ependymal-subependymal enhancement, (3) widened irregular tentorial enhancement, or (4) communicating hydrocephalus. Thirteen (59.6%) of these 22 patients had associated parenchymal metastases. Recognition of leptomeningeal disease may alter the management of patients with parenchymal metastases. Communicating hydrocephalus in cancer patients should be considered to be related to leptomeningeal metastasis until proven otherwise.

Entities:  

Mesh:

Year:  1984        PMID: 6333146     DOI: 10.2214/ajr.143.5.1035

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  5 in total

Review 1.  Meningeal metastases: clinical aspects and diagnosis.

Authors:  F Formaglio; A Caraceni
Journal:  Ital J Neurol Sci       Date:  1998-06

2.  The clinical features of spinal leptomeningeal dissemination from malignant gliomas.

Authors:  Jung-Sik Bae; Seung-Ho Yang; Woan-Soo Yoon; Seok-Gu Kang; Yong-Kil Hong; Sin-Soo Jeun
Journal:  J Korean Neurosurg Soc       Date:  2011-06-30

Review 3.  Leptomeningeal metastases from solid malignancy: a review.

Authors:  Sophie Taillibert; Florence Laigle-Donadey; Catherine Chodkiewicz; Marc Sanson; Khê Hoang-Xuan; Jean-Yves Delattre
Journal:  J Neurooncol       Date:  2005-10       Impact factor: 4.130

4.  CT of diffuse leptomeningeal metastasis from primary extracerebral neuroblastoma.

Authors:  R N Sener
Journal:  Pediatr Radiol       Date:  1993

Review 5.  Leptomeningeal metastases: a review of evaluation and treatment.

Authors:  M C Chamberlain
Journal:  J Neurooncol       Date:  1998-05       Impact factor: 4.130

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.